End-of-day quote
Shenzhen S.E.
03:30:00 17/05/2024 am IST
|
5-day change
|
1st Jan Change
|
7.15
CNY
|
-0.14%
|
|
-0.97%
|
-9.15%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3,160
|
3,679
|
3,876
|
3,856
|
3,966
|
4,023
|
Enterprise Value (EV)
1 |
1,733
|
2,103
|
2,559
|
2,369
|
2,134
|
2,515
|
P/E ratio
|
13.1
x
|
25.3
x
|
59.5
x
|
32
x
|
37.2
x
|
39.8
x
|
Yield
|
2.71%
|
2.33%
|
1.3%
|
1.31%
|
1.29%
|
1.27%
|
Capitalization / Revenue
|
1.09
x
|
1.45
x
|
1.55
x
|
1.37
x
|
1.48
x
|
1.44
x
|
EV / Revenue
|
0.6
x
|
0.83
x
|
1.02
x
|
0.84
x
|
0.8
x
|
0.9
x
|
EV / EBITDA
|
5.24
x
|
6.9
x
|
8.83
x
|
8.27
x
|
12.5
x
|
13.2
x
|
EV / FCF
|
4.59
x
|
2.83
x
|
-15,083
x
|
43.4
x
|
-15.8
x
|
-60.5
x
|
FCF Yield
|
21.8%
|
35.4%
|
-0.01%
|
2.31%
|
-6.32%
|
-1.65%
|
Price to Book
|
1.15
x
|
1.28
x
|
1.36
x
|
1.32
x
|
1.27
x
|
1.32
x
|
Nbr of stocks (in thousands)
|
5,04,000
|
5,04,000
|
5,04,000
|
5,04,000
|
5,10,400
|
5,11,136
|
Reference price
2 |
6.270
|
7.300
|
7.690
|
7.650
|
7.770
|
7.870
|
Announcement Date
|
25/03/19
|
30/03/20
|
29/03/21
|
28/03/22
|
24/03/23
|
29/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,899
|
2,535
|
2,504
|
2,809
|
2,671
|
2,786
|
EBITDA
1 |
330.9
|
304.9
|
289.9
|
286.3
|
171.2
|
190.3
|
EBIT
1 |
210.6
|
186
|
173.7
|
167.6
|
51.03
|
65.24
|
Operating Margin
|
7.26%
|
7.34%
|
6.94%
|
5.97%
|
1.91%
|
2.34%
|
Earnings before Tax (EBT)
1 |
361.5
|
247.4
|
125.1
|
194.8
|
127.8
|
118.4
|
Net income
1 |
241.8
|
145.3
|
65.14
|
120.6
|
105.3
|
99.65
|
Net margin
|
8.34%
|
5.73%
|
2.6%
|
4.29%
|
3.94%
|
3.58%
|
EPS
2 |
0.4797
|
0.2883
|
0.1292
|
0.2393
|
0.2089
|
0.1977
|
Free Cash Flow
1 |
377.6
|
743.5
|
-0.1696
|
54.63
|
-134.9
|
-41.61
|
FCF margin
|
13.02%
|
29.33%
|
-0.01%
|
1.95%
|
-5.05%
|
-1.49%
|
FCF Conversion (EBITDA)
|
114.09%
|
243.83%
|
-
|
19.08%
|
-
|
-
|
FCF Conversion (Net income)
|
156.16%
|
511.64%
|
-
|
45.29%
|
-
|
-
|
Dividend per Share
2 |
0.1700
|
0.1700
|
0.1000
|
0.1000
|
0.1000
|
0.1000
|
Announcement Date
|
25/03/19
|
30/03/20
|
29/03/21
|
28/03/22
|
24/03/23
|
29/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,427
|
1,576
|
1,317
|
1,486
|
1,832
|
1,507
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
378
|
744
|
-0.17
|
54.6
|
-135
|
-41.6
|
ROE (net income / shareholders' equity)
|
9.17%
|
5.51%
|
2.73%
|
4.39%
|
3.18%
|
2.93%
|
ROA (Net income/ Total Assets)
|
3.4%
|
2.89%
|
2.57%
|
2.4%
|
0.71%
|
0.9%
|
Assets
1 |
7,111
|
5,027
|
2,532
|
5,028
|
14,841
|
11,114
|
Book Value Per Share
2 |
5.430
|
5.710
|
5.670
|
5.810
|
6.120
|
5.950
|
Cash Flow per Share
2 |
1.920
|
2.910
|
2.610
|
2.980
|
3.060
|
2.800
|
Capex
1 |
136
|
126
|
291
|
163
|
310
|
186
|
Capex / Sales
|
4.71%
|
4.96%
|
11.64%
|
5.79%
|
11.59%
|
6.69%
|
Announcement Date
|
25/03/19
|
30/03/20
|
29/03/21
|
28/03/22
|
24/03/23
|
29/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -9.15% | 62Cr | | +32.09% | 69TCr | | +29.39% | 58TCr | | -1.34% | 37TCr | | +20.34% | 33TCr | | +7.39% | 29TCr | | +14.25% | 24TCr | | -3.03% | 21TCr | | +10.02% | 21TCr | | +8.49% | 17TCr |
Other Pharmaceuticals
|